KRAS and neoplasm: KRAS with distinct mutations at amino acids G12, G13, and Q61 is associated with tumor aggressiveness and unfavorable patient prognosis.[9] The successful development of specific inhibitors against KRASG12C variant signifies a remarkable advancement in the realm of KRAS‐targeted therapies.